Scottish biotech Lentitek Ltd has raised a total of £1 million in funding to advance its next-generation cancer technology, combining £700,000 in private investment led by Equity Gap with a £300,000 grant from Innovate UK.
The Edinburgh-based company is developing manufacturing technologies for lentiviral vectors, a critical component in CAR-T cell and gene therapies used to treat cancer and genetic diseases. The funding will support efforts to scale production and accelerate commercialisation, addressing a key bottleneck in making advanced therapies more accessible.
Existing investors, including Gabriel Investment Syndicate, Apollo Informal Investment and Scottish Enterprise, also participated in the round.